CYDY - Cytodyn And COVID-19: The Endgame Is On
Let everyone follow his own belief, for, as you know, there is an immense variety of opinions and freedom of judgement. - Petrarch, Secretum
In July, Cytodyn (CYDY) is facing a key binary event, two readouts on the COVID-19 trials it initiated back in April. Strong positive results on either trial promise significant short-term upside, despite the strong run-up during the last months. If the COVID-19 trials should fail or results turn out to be lackluster, long-term investors focused on leronlimab's prospects in HIV, cancer, NASH and immunological/inflammatory diseases might find a very attractive entry